(SeeNews) - Jul 21, 2011 - Anglo-Swedish pharma major AstraZeneca plc (LON:AZN, STO:AZN) said late on Wednesday its experimental blood thinner Brilinta was approved by the US Food and Drug Administration (FDA).
By 1002 CET on Thursday, the company's shares had climbed 3.08% to SEK 324.80 on the stock exchange in Stockholm.
Brilinta is an oral antiplatelet drug indicated to reduce the risk of heart attacks and cardiovascular death in patients with acute coronary syndrome (ACS). The FDA made its decision, which had been postponed on several occasions, based on the so-called Plato trial, …
Комментариев нет:
Отправить комментарий